Manufacturing

Articles

The collaboration will combine N4’s nanoparticle delivery system with SRI’s molecular guidance system.

N4 Pharma and SRI to Collaborate on Intracellular Delivery to Specific Target Cells

In a new agreement, Cellares will utilize its Cell Shuttle fully automated cell therapy manufacturing platform to manufacture select CAR-T cell therapies under development by Bristol Myers Squibb. 

Bristol Myers Squibb to Access Cellares' Cell Therapy Manufacturing Platform in New $380 Million CAR-T Cell Therapy Deal

Feliza Mirasol is the science editor for 

With the launch of a new manufacturing service, Memel Biotech will offer services for discovery through to formulation for advance therapy medicinal products.

Memel Biotech to Offer ATMP Manufacturing at Lithuania Site

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Videos

Can Cellares deliver on the goal to meet total patient demand for cell therapies globally? CEO Fabian Gerlinghaus discusses.

Automation of Clinical Data Key in Meeting Cell and Gene Therapy Demand

Univercells and Altamira Therapeutics are collaborating on nanoparticle-delivered mRNA vaccines, while Andelyn Biosciences and Grace Science are partnering on novel therapies for NGLY1 deficiency.

Univercells and Andelyn Biosciences Form Separate Drug Development Partnerships

Cellares CEO Fabian Gerlinghaus discusses the nuts and bolts of counterflow centrifugal elutriation and electroporation innovations and optimization, while hinting at big news on future release testing of products, as a product itself.

Cellares Cell Shuttle is More Valuable Than the Sum of the Value of the Individual Parts

In a new manufacturing pact, Chime Biologics will produce DT-7012, Domain Therapeutics' antibody candidate for treating cancer that will soon be entering Phase I studies.

Chime Biologics to Manufacture Novel Antibody Cancer Immunotherapy for Domain Therapeutics

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Activation and expansion are essential for success in both autologous and allogeneic therapies.

Development of Gamma-Delta T-Cell Therapies

CSL will share access to Cytegrity, its proprietary stable production system for lentiviral vector production, with Genezen. 

CSL Licenses Cytegrity Lentiviral Vector Production System to Genezen

FDA has approved Iovance Biotherapeutics’ Amtagvi (lifileucel) for treating patients with unresectable or metastatic melanoma.

Manufacturing, Cell Therapies